Prostate cancer is the most common non-cutaneous form of cancer affecting men; and the second most common cause of cancer-related death in the USA and the third most common in Europe 1 . Approximately 25-30% of men who initially present with localized or locally-advanced disease will have recurrence of their cancer and many will require systemic treatment with androgen-deprivation therapy (ADT). While ADT can control disease progression for some years, the disease will ultimately progress to castration-resistant prostate cancer (CRPC), which requires the addition of different therapeutic approaches. Unfortunately the majority of patients that present with advanced-stage or metastatic prostate cancer will progress to CRPC, despite an initial response to ADT , particular have come under intense scrutiny as they are invariably expensive and their actual benefits to patients, let alone society, are often incompletely measured and poorly elucidated. Increasing numbers of men worldwide have mCRPC and want access to novel therapies that, although approved, might not be available having failed health technology assessments, often owing to a perceived lack of cost-effectiveness. Traditional clinical outcomes, such as progression-free survival (PFS) and overall survival, are well measured in trials, but patient perspectives, in general, are not as well captured. Frequently, the quality of the evidence and knowledge available concerning issues other than patient survival, which might influence decision makers, is inadequate. Currently, there is too much of a reliance on clinicians' recording of adverse events within trials rather than obtaining this information directly from patients; as a consequence, many adverse effects go under-reported, under-recognized and undertreated. Not only is the reliability of adverse event ratings reported among clinicians poor (two-point differences between patients' and clinicians' ratings of certain adverse events can be as frequent as 18% in patients with certain symptoms) 10 , but patients' patient-reported outcomes (PRO) reports, including those from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 11 , reveal that they record many symptoms more frequently, and at a greater severity, than clinicians using the CTCAE criteria
. Docetaxel plus prednisone, in combination with ADT is the most common first-line chemotherapy treatment for metastatic CRPC (mCRPC) 3 . The availability of more-novel agents, including radium-223 dichloride [
223 Ra] 4 , particular have come under intense scrutiny as they are invariably expensive and their actual benefits to patients, let alone society, are often incompletely measured and poorly elucidated. Increasing numbers of men worldwide have mCRPC and want access to novel therapies that, although approved, might not be available having failed health technology assessments, often owing to a perceived lack of cost-effectiveness. Traditional clinical outcomes, such as progression-free survival (PFS) and overall survival, are well measured in trials, but patient perspectives, in general, are not as well captured. Frequently, the quality of the evidence and knowledge available concerning issues other than patient survival, which might influence decision makers, is inadequate. Currently, there is too much of a reliance on clinicians' recording of adverse events within trials rather than obtaining this information directly from patients; as a consequence, many adverse effects go under-reported, under-recognized and undertreated. Not only is the reliability of adverse event ratings reported among clinicians poor (two-point differences between patients' and clinicians' ratings of certain adverse events can be as frequent as 18% in patients with certain symptoms) 10 , but patients' patient-reported outcomes (PRO) reports, including those from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 11 , reveal that they record many symptoms more frequently, and at a greater severity, than clinicians using the CTCAE criteria 11 . The appropriate reporting of certain adverse effects might have far more relevance to the decision-making process of men with prostate cancer than is currently realized; for example, what might be termed 'relatively minor symptoms' by a clinician could have a profound effect on certain individuals and strongly influence their treatment choices 12 .
Men with mCRPC report significantly poorer quality-of-life (QoL) than groups of men with prostate cancer of a less-advanced stage, with priority areas being fatigue, pain and decreased physical activity 13 . From the patient's perspective, optimal treatment of advanced-stage prostate cancer might be a function of the patient's willingness and Sipuleucel-T (an autologous cellular immunotherapy) 5 , has expanded the treatment options. Advanced-stage prostate cancer is not uniformly refractory to further manipulation of androgen levels or androgen signalling, and disease progression has been shown to depend on androgen synthesis and androgen receptor interactions 6, 7 . CRPC, which is still hormone-sensitive, has been characterised by a response to drugs such as abiraterone (an androgen biosynthesis inhibitor) and enzalutamide (an androgen receptor inhibitor). These compounds have demonstrated survival benefits for patients with metastatic prostate cancer in phase III clinical trials in the docetaxel-naive setting, and also in men whose disease has progressed after chemotherapy [6] [7] [8] [9] . Second-line chemotherapy with cabazitaxel has also demonstrated benefits in overall survival when compared with the use of mitoxantrone in this setting 2 . Many investigators have raised concerns about the infinite demands being made on finite healthcare budgets. Cancer drugs in to make trade-offs between efficacy and tolerability. Treatment choices involve complex decision-making processes that might not always seem rational to a clinical scientist. Even when the information provided is optimal, individual patients might have preferences influenced by expectations about their likely ability to continue to pursue hobbies, employment, and/or other activities. Substantive data regarding these salient issues from a patient's perspective are often missing. Communication with health-care professionals (HCPs) on the likely outcomes of treatment is key, and patients with metastatic cancer may need considerable help in assimilating information about their disease and treatment goals; many patients have quite unrealistic perceptions of their prognoses and the therapeutic intent, and likely adverse effects of treatment, which often affects their decision making. The knowledge and perceptions these HCPs themselves might have of the effects of treatments on more patient-related concerns is uncertain, especially if data on QoL outcomes are generally unavailable 14 . For these reasons, ASCO published a working group statement in 2014 on the need for new clinical benefit scales in clinical oncology 15 and, in 2015, its European counterpart (ESMO) published a paper describing the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) 16 . The authors of the ESMO-MCBS recognized that the outcomes of trials of novel drugs could range from trivial improvements in PFS to many months or years of extended survival, thus indicating the need for an indication of more clinically meaningful benefit. Ultimately, this scale should include data from good quality PROs to enable a more-comprehensive evaluation of clinical benefit 16 .
Patient-reported outcome measures
Both the FDA and the EMA have recognized that obtaining good quality data from patient-reported outcome measures (PROMs) is important when evaluating drugs in patients for whom palliation of symptoms is an important therapeutic goal; consequently, both agencies have published guidance and recommendations for use of PROMs in clinical trials 17, 18 . Despite these recommendations, an analysis of ClinicalTrials.gov entries (2007) (2008) (2009) (2010) (2011) (2012) (2013) identified only 29% (3,947 out of 13,584) of all registered oncology trials in this period as declaring the use of one or more PROM, and merely 18% (2,453 out of 13,584) of that PROs such as pain assessment and the PROMIS and PRO-CTCAE scales be included in the designs of all trials testing treatments of mCRPC.
Enzalutamide. Two trials designed to assess the efficacy of enzalutamide also provided extensive data on PROs. Fizazi and colleagues 22 reported the clinical end points and overall QoL outcomes of patients participating in the AFFIRM trial, but a more detailed QoL analysis was provided in a separate publication by Cella and colleagues 23 , and showed that patients treated with enzalutamide had significantly improved QoL outcomes compared with those treated with placebo. After 25 weeks of treatment, the FACT-P total score decreased by 1.52 points in patients who received enzalutamide, compared with a decrease of 13.73 points in those who received placebo (P <0.001), reflecting a significantly greater deterioration in the QoL of men receiving placebo. In addition, significant treatment differences (all P <0.05) favouring the use of enzalutamide were observed according to all FACT-P subscales and indices, including pain, whether analysed using a mixed-effects model for repeated measures that assumes missing data are at random, or a pattern-mixed model that assumes missing data are not at random.
In the PREVAIL trial 24 , QoL and pain were measured at baseline using the FACT-P, the EuroQol five dimensions questionnaire (EQ-5D) and the Brief Pain Inventory (Short Form) (BPI-SF) and thereafter at regular periods throughout study treatment. Improvement in QoL was defined as an increase, and deterioration as a decrease, in the score at any post-baseline assessment and the significance of these changes was defined using predetermined thresholds. These thresholds were based on changes in score range that reflect clinically meaningful effects on patients. The authors detailed succinctly the components of the questionnaires in a table for ease of reference. The results showed that treatment with enzalutamide, compared with placebo, resulted in a significantly reduced risk of, and delayed time to QoL deterioration, pain progression and occurrence of skeletal-related events (SREs) (TABLE 1).
Abiraterone. A comprehensive series of publications are available reporting PROs of patients in the phase III COU-AA-301 study, a double-blind placebo-controlled trial designed to test the efficacy of abiraterone plus prednisone versus placebo these trials listed a PRO as a primary or secondary outcome measure 19 . Data from this study showed an increase in the use of PROMs since the publication of the FDA-PRO guidelines 15 , although the continued omission of PROs from many clinical trials is a sorry reflection on the lack of value placed on such measures.
The aim of this Perspectives is to critique publications over the past 5 years, of data from trials designed to investigate mCRPC treatments where the therapeutic aims include control of progression and amelioration of the symptoms of this disease. We aimed to determine the quality of any PRO data provided by these studies. Our approach was not to conduct a systematic review, although criteria similar to those specified by Calvert and colleagues 20 were used when making some evaluations of the quality of studies. We considered five areas of interest: identification of PROs as a primary or secondary outcome; hypothesis and relevant domains described; evidence provided or cited on the validity and reliability of the PRO; explicit statements about statistical approaches for dealing with missing data; and some discussions of PRO-specific limitations of study findings and/or generalizability of results to other patient populations and areas of clinical practice. For us to consider the reports to be examples of 'good' quality, a report had to satisfy at least four of these criteria and demonstrate convincingly that the investigational drug had improved patients' QoL or pain outcomes as well as providing efficacy compared with the control group. We deemed publications as 'adequate' if only three criteria were satisfied, and 'poor' if any improvements were not compelling and/or two, or fewer key criteria were mentioned.
Effects on QoL and pain
Several different types of PROMs have been reported in trials of mCRPC treatments in the past 5 years
. Some of these measures (such as the Brief Pain Inventory) are generic and appropriate for use with all cancer types and at all stages of disease; others (such as the Functional Assessment of Cancer Therapy-Prostate; FACT-P) are more specific and probe the issues that men with prostate cancer have highlighted to be of most relevance to them. The choice of outcome instrument used in a clinical trial often depends on the outcomes that investigators expect treatment to influence the most. In a Prostate Cancer Clinical Trials Working Group 2016 publication by Scher and colleagues 21 , the authors recommend plus prednisone. The pain, QoL and fatigue analyses of data from this trial were published separately [25] [26] [27] . Pain was assessed using the BPI-SF at baseline, day 15 of cycle one and day 1 of each treatment cycle thereafter until treatment discontinuation 25 . Patients' analgesia use and time to occurrence of each SRE was also measured. Completion rates of the BPI-SF were high, with 93.6% of planned assessments completed during the study, and the authors used prospectively defined response criteria. Pain palliation was assessed in those who had clinically significant baseline pain, whereas all other analyses were conducted on an overall intention-to-treat basis. The trial results showed that abiraterone plus prednisone provided significantly more effective and faster pain palliation than placebo plus prednisone in patients with clinically significant pain at baseline, as well as delaying the time to first SRE 25 (TABLE 1). Harland and colleagues 26 , reported the QoL data from the same trial using the FACT-P questionnaire. The analysis was performed only on data from patients with clinically significant functional impairment at baseline, on the basis that patients without any notable functional impairment could not have any improvement in QoL. Arguably, a clearer picture of how the drugs affect QoL might have been achieved if a responder analysis showing the proportion of patients whose QoL was improved, deteriorated or unchanged over time had been included. Significant improvements in the FACT-P total score in favour of abiraterone were noted (P <0.0001) in all subscale scores, apart from social and/or family wellbeing. Sternberg and colleagues 27 analysed and described the reported fatigue results from the same study using the Brief Fatigue Inventory. The questionnaire was completed at baseline (approximately 14 days before the first dose of study treatment) and on the first day of each treatment cycle until treatment was discontinued. Clinically meaningful changes were pre-specified before conducting the analyses and, similar to Harland et al. 26 , analyses were confined to those with clinically significant fatigue at baseline (defined as scores of >5). The report demonstrated that abiraterone and prednisone provide substantial and meaningful improvements in self-reported fatigue in patients with mCRPC that had progressed after docetaxel chemotherapy 27 . Basch and colleagues 28 used the FACT-P and BPI-SF to examine QoL and pain palliation, respectively in the phase III COU-AA-302 trial, comparing QoL deterioration. In summary, all of these publications together indicate that treatment with abiraterone and prednisone, relative to prednisone alone or with placebo, significantly improves patients' outcomes in terms of efficacy, pain control and QoL (TABLE 1) .
the efficacy of abiraterone plus prednisone versus prednisone alone in men with chemotherapy-naive mCRPC 28 . The analyses of pain outcomes were detailed, and showed that abiraterone and prednisone delayed time to progression of mean pain intensity and pain interference, as well as time to A generic health-outcome instrument that provides a simple descriptive profile and a single index value or utility score that indicates health status. This instrument comprises five different dimensions: mobility, self-care, usual activities, pain and/or discomfort and anxiety and/or depression. Each dimension has a three-category response scale: no problems, some problems and extreme problems.
EORTC-C30 (REF. 42)
A 30-item, generic cancer questionnaire that consists of five functional scales (physical, role, emotional, cognitive and social and a global-health scale, three multi-item symptom scales (fatigue, nausea/vomiting and pain) and six single-item scales (dyspnoea, sleep, appetite, constipation, diarrhoea and financial difficulties owing to disease). Response categories have four levels from 'not at all' to 'very much' and two items for overall physical condition and quality of life, which use a seven-point scale. All scores from these scales and from single-item measures range from 0 to 100. A high scale score for global health status represents better quality of life.
PR25 (REF. 43)
A supplementary module to use in combination with the EORTC-C30 for prostate-specific issues, consisting of 25 items assessing urinary and bowel symptoms, sexual activity and function, and side effects of therapy.
FACT-P 44
An additional subscale of the FACT-G generic core questionnaire with 12 prostate-related specific concerns. All items are rated on a Likert scale from 0 to 4. The questionnaire produces an overall QoL score (FACT total) and subscale scores. Higher sum scores indicate a better quality of life. Summation of the physical, functional and prostate subscale scores produces a Treatment Outcome Index (FACT-TOI), which is considered the most sensitive indicator of patient-related health outcomes in randomized controlled trials comparing two or more different treatments.
BPI-SF 45
A 9-item questionnaire recommended for use in clinical trials that is designed to assess pain intensity and the interference of pain with daily life. No scoring algorithm is included, but 'worst pain', or the arithmetic mean of the four severity items, is used to assess pain severity. 'Pain intensity' is recorded as the worst pain in the past 24 hours. 'Pain interference' is the mean score of all seven items assessing the influence of pain on emotional wellbeing and physical activity, providing an overall interference score.
McGill-Melzack

46
A questionnaire used by patients to quantify their pain sensations over time and to determine the effectiveness of any intervention. This questionnaire comprises 78 words, from which respondents choose those that best describe their pain experience. Scores are tabulated by summing values associated with each word; scores range from 0 (no pain) to 78 (severe pain).
McCaffery VAS 47
This is a unidimensional visual analogue scale rating for pain, with 0 representing no pain and 10 representing pain that is intolerable.
BFI 48
A questionnaire used to assess the severity and effect of cancer-related fatigue on daily functioning in the past 24 hours. Patients complete visual analogue scales enabling fatigue to be rated on a scale from 0-10, including their current level of fatigue, usual level of fatigue, and worst fatigue in the past 24 hours, followed by the interference of fatigue with general level of activity, mood, walking, work, relationships, and enjoyment of life. A global fatigue score is obtained by averaging all the items on the BFI. 
24
Phase III RCT; enzalutamide (872 patients) versus placebo (845 patients); PROs included FACT-P at baseline and during treatment, EQ-5D plus VAS at baseline and during treatment and BPI-SF at baseline and at weeks 13 and 25
Enzalutamide superior to placebo in terms of: median time to deterioration in FACT-P total score 11.3 versus 5.6 months (P <0.0001); clinically meaningful improvements in FACT-P, EQ-5D and VAS (all P <0.0001); progression of worst pain in 29% versus 42% (P <0.0001) at week 13 but not at week 25 
26
QoL aspect of phase III RCT; PROs measured using FACT-P at baseline and on day 1 of cycles 1, 4, 7, 10 and every six cycles until end of study treatment Abiraterone + prednisone superior in terms of: significant improvements FACT-P total score 48% versus 32% (P <0.0001); longer median time to deterioration in FACT-P total score (P <0.0001); similar differences were observed in all FACT-P subscales, with the exception of the social/family wellbeing domain, median time to improvement in the physical wellbeing domain; trial outcome index was significantly shorter (P <0.01) Pain and fatigue aspect of phase III RCT; PROs measured using the BFI at baseline (~14 days before the first dose of study treatment) and on the first day of each treatment cycle until treatment discontinuation
Abiraterone + prednisone superior in terms of improvement in clinically significant fatigue at baseline (58% versus 40%, P = 0.0001), improved fatigue interference (55% versus 38%, P = 0.0075), and accelerated improvement in fatigue intensity (P = 0.0155)
Good study but again, analyses confined to those with fatigue at baseline COU-AA-302 Basch et al.
28
Phase III RCT; abiraterone + prednisone (546 patients) versus placebo + prednisone (542 patients) in chemotherapy-naive patients; PROs measured using BPI-SF at screening, day 1 of each treatment cycle and at treatment end; FACT-P on the first day of cycles 1, 3, 5, 7 and then the first day of every third cycle and at treatment discontinuation Abiraterone + prednisone superior in terms of: median time to mean pain intensity, 26.7 versus 18.4 months (P = 0.049); and median time to pain interference with daily activities, 10.3 versus 7.4 months (P = 0.005); abiraterone + prednisone significantly delayed time to QoL deterioration as assessed by FACT-P total score, general function and trial outcome index composite scores, prostate-cancer-specific scores, and all subscale scores (P <0.001) except for social and family wellbeing. Median times to progression of worst pain intensity were similar between groups
Good reporting of data from BPI, but only reported overall QoL scores 
33
Phase II study of Lu-EDTMP for bone pain relief in patients with bone metastases; 32 patients had mCRPC, 12 had mBC; PROs recorded in a daily diary using the McCaffery visual analogue pain scale; pain relief assessed in terms of changes in average baseline pain versus average scores at 1,2,4,5,7,12 and 16 weeks; KPS used to measure QoL 177 Lu-EDTMP deemed safe and effective alternative for bone pain palliation in patients with metastatic disease, no significant differences in efficacy or toxicity observed between different doses; progressive decrease in pain from baseline observed on VAS for up to 4 weeks (P <0.05); improvements in QoL also observed on the KPS but this is not a PRO Poor choice of instrument to measure QoL (the KPS), also a very small cohort size and little information about data handling 35 Pooled data analysed from three identically designed phase III RCTs; sc denosumab 120 mg versus IV zoledronic acid 4 mg monthly in patients with bone metastases from cancer (2,046 with breast cancer, 1,901 with prostate cancer and 1,597 with solid tumours); PROs were measured using the BPI-SF for pain severity analyses. A score of ≤4 was considered no, or mild pain and scores of >4 considered moderate to severe pain; seven items from the BPI-SF measured pain interference with general activity, walking, work, mood, enjoyment of life, relations with others and sleep; FACT-G also completed at each monthly visit Denosumab superior in terms of: delayed mean time to onset of moderate/severe pain 6.5 versus 4.7 months (P <0.001) and delayed onset of overall pain interference 10.3 versus 7.7 months (P <0.001) by 1.8 months in those with no and/or mild pain at baseline; fewer denosumab treated patients experienced clinically meaningful worsening from baseline Good analyses but pooling of data across cancer sites makes it difficult to determine exactly the benefits to patients with mCRPC BPI-SF, Brief Pain Inventory (short form); CDF, cumulative distribution function; ECOG, Eastern Cooperative Oncology Group; EORTC-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D, EuroQol five dimensions questionnaire; FACT-G, Functional Assessment of Cancer Therapy-General; FACT-P, Functional Assessment of Cancer Therapy-Prostate; HRQoL, health-related quality of life; IV, intravenous; KPS, Karnofsky performance status;
177
Lu-EDTMP,
177
Lu-ethylenediamine-tetra-methylene phosphonic acid; mBC, metastatic bladder cancer; mCRPC, metastatic castration-resistant prostate cancer; PRO, patient-reported outcome; QoL, quality of life; RCT, randomized controlled trial; sc, subcutaneous; VAS, visual analogue scale.
Docetaxel. Data on self-reported QoL outcomes from a randomized phase II trial investigating the efficacy of docetaxel with or without estramustine were collected using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ C30), the BPI, and patient-reported analgesia use 29 . Data from 59 of 79 patients were included in the analysis. The authors reported the proportions of patients whose QoL outcomes improved, remained stable or worsened from baseline, and no significant changes were revealed in either the EORTC-QLQ C30 scales or BPI scores during treatment. Probably the most interesting feature of this study was the finding that the baseline QoL measurements enable treatment-responders and non-responders to be identified; those patients who responded to treatment also had a significantly better baseline QoL (P = 0.003).
Results of a phase II randomized controlled trial 30 , in which men received either continuous (n = 75) or monthly intermittent (n = 73) docetaxel treatment failed to show any significant differences in patients' QoL outcomes (as quantified using the EORTC QLQ C−30) or pain reporting (using the BPI-SF). These differences, however, might have been caused by the timing of the assessments. Despite QoL being cited as the primary outcome of the study, the publication lacks important details such as how the analyses were conducted 30 (TABLE 1) .
Cabazitaxel. The TROPIC trial is a prospective phase III randomized controlled trial designed to test the efficacy of cabazitaxel versus mitoxantrone in a cohort of 755 patients with mCRPC who had progressed during, or after docetaxel-based chemotherapy 2 . Follow-up pain and QoL outcomes were measured retrospectively using the McGill-Melzack pain questionnaire in a subgroup of patients who had survived for 2 years 31 . In this study, Eastern Cooperative Oncology Group score was used to indicate QoL; however, this measure is not patient reported, rather this is a performance score, which is assessed and completed by the clinician. The sample size was small, reporting of pain data was poor, and unsurprisingly, no significant differences were found between the two groups.
In a follow-on phase III/IV trial designed to facilitate access to cabazitaxel and to more formally evaluate QoL, 112 men with mCRPC completed the EQ-5D with the general 'health today' visual Denosumab. The final paper reports results from a pooled analysis of three identically designed, randomized, double-blind, phase III studies comparing subcutaneous denosumab with intravenous zolendronic acid in 5,544 patients with bone metastases, 1,901 of whom were men with mCRPC 35 . Analysis of the data showed that denosumab significantly delayed time to an increase in pain severity in those with pain at baseline and delayed the onset of pain for those with no, or mild pain at baseline. The statistical approach to this analysis is very thorough, although the use of pooled analyses makes it hard to determine the true benefits derived by patients with prostate cancer (TABLE 1) .
Discussion
Both disease burden and treatments of mCRPC can have a deleterious effect upon patients' QoL. Pain is the most frequently observed symptom in men with mCRPC, and appropriate analgesia is often underused 13, 36 . In comparison to men with non-metastatic, or localized prostate cancer, those with mCRPC report significantly worse QoL, owing to pain, fatigue, and decreased physical activity 37 . Data on these areas of concern need to be captured fully when palliation is a therapeutic aim. In the past decade, PROs have been included in treatment trials, but usually as secondary end points, with the exception of a few phase II studies 30, 33, 34 . Unfortunately, several reports contained opaque, post-hoc exploratory analyses, with little or no clear evidence that the patient-reported end points chosen had been established a priori. Much of the published work, with the exception of some of those identified in this Perspectives article, was characterised by inappropriate selection of outcome measurement instruments, poor statistical analyses and/or limited reporting and/or inadequate interpretation of results. The statistical analyses in some, but not all papers scrutinised in this article included comparisons of mean scores at only one time point and no references to changes from baseline, to responder analyses and/or cumulative distribution function plots. Not all reports determined or used the published minimally important differences or clinically meaningful differences when comparing any changes in scores. Details on the handling of missing data, such as any imputation used, and sensitivity analysis to test whether or not data were truly missing at random intervals and, therefore, not ignorable when reported were included in remarkably few studies.
analogue scale (VAS) at baseline, following alternate treatment cycles and at the end of treatment 32 . The choice of this instrument (used predominantly to provide a utility score for use in health economic models) limited the ability to collect comprehensive information on any toxicities from a patient's perspective and few formal analyses were carried out, despite the claim of a trend towards significant improvements in QoL (TABLE 1) . The effect of this treatment was documented by patients' self-assessment of pain using a VAS, the BPI and self-reported analgesia use. As is the case with many studies of patients with metastatic disease, few patients from the original cohort survived a sufficient period of time to enable long-term follow-up monitoring; data were available on 32 and eight of the original 100 patients at 12 and 24 months, respectively. Pain relief (measured using VAS and analgesia use) was the primary end point of this study, and was used to classify patients as responders (improvement in pain), who had reduced pain and stable analgesic consumption, or non-responders. Results showed that up to 71% of patients had a pain response at week 8 after a single 223 Ra injection. However, the small cohort of patients and incomplete follow-up of these patients limits the generalizability of the results (TABLE 1) .
177
Lu-EDTMP. In a phase II randomized controlled trial, Agarwal and colleagues 34 examined the efficacy of high versus low doses of 177 Lu-ethylenediamine-tetra-methylene phosphonic acid (EDTMP) for bone pain relief in patients with bone metastases in a cohort of 32 patients with prostate cancer and 12 with breast cancer. In this trial, investigators used the McCaffery VAS to measure pain, and the Karnofsky Performance Score (KPS) for QoL. Pain relief was assessed in terms of changes in mean baseline pain from mean scores at 1, 2, 4, 5, 7, 12 and 16 weeks. The investigators reported a progressive decrease in pain on the VAS from baseline up to 4 weeks, and claimed an improvement in QoL for all patients. However, the KPS is not a PRO measure but a clinician-completed performance scale originally designed to determine nursing workload and staffing requirements (TABLE 1) .
The quality of the analyses and reporting of PROs was variable among the study reports included in this Perspective, and was often dependent upon whether or not PROs had been reported in separate publications from those containing the main efficacy outcomes, or in comprehensive series of publications, such as those from the COU-AA-301 studies [25] [26] [27] . This is, of course, a dilemma given that many researchers and journals give priority to papers containing more-traditional safety data and adverse-event reporting, often leaving little space for secondary end points such as PROs.
The continued dearth of quality PRO data from patients for whom palliation of symptoms is essential is both disappointing and surprising. The EMA provides broad recommendations on health-related QoL in the context of clinical trials 18 , and the FDA has issued formal guidance-setting standards for use of PROMs in support of product labelling claims 17 . In an interesting paper published online in 2011 (REF. 38 ) the authors explored the reasons for rejection of PRO-based label claims among new molecular and biological license applications. This study revealed that the FDA specifically questioned the validity of contents and/or PRO measurement instruments in general; frequent issues associated with the study design, data quality, or interpretation of results existed 38 .
Conclusions
The increasing numbers of therapeutic endeavours intended to improve the outcomes of men with mCRPC is welcome. Unfortunately, data on PROs emerging from clinical trials in the past 5 years are still both quantitatively and qualitatively insufficient. Importantly, even less is known about the effects of novel therapies when used in other clinical settings, in which patients might have comorbidities and/or characteristics that make them ineligible for treatment within a trial. Routine collection of a standard set of data on outcomes, such as those recommended for trials in patients with prostate cancer 39 , or more recently, others developed by the International Consortium for Health Outcomes Measurement (ICHOM) group 40 , which come directly from patients in the clinic, might be invaluable to build up sufficient 'real-world' data to aid decision-making.
In the past decade, many novel interventions have been shown to extend the lives of men with mCRPC, but, if patients and their physicians are to make wise
